Novavax, a vaccine undergoing trials for effectiveness against the novel coronavirus, has become the first immune dose to definitively confirm protection against the new variant of the deadly virus which was detected in the UK late last year.
The massive blaze ravaged three to four floors of the upcoming facility in Manjari that was scheduled to become operational within a month or so.
Serum Institute of India (SII), Pune on Thursday announced a compensation of Rs 25 lakh to each family who have lost their loved ones in the fire incident today.
The SII has partnered with Novavax Inc to manufacture its potential Covid-19 vaccine for India and other countries.
Adar Poonawalla took to Twitter and shared a video on his account of taking the Covishield vaccine himself which has been manufactured by his company.
As nationwide Covid-19 vaccination drive begins, Serum Institute of India (SII) CEO Adar Poonawalla on Saturday received Covid-19 vaccine - Covidshield in Pune.
Pune-based Serum Institute of India (SII) on Tuesday rolled out the first consignment of over 56 lakh doses of Covishield vaccine for 13 cities across the country, four days ahead of a massive pan-India inoculation drive against COVID-19.
Serum Institute of India (SII) Chief Executive Officer Adar Poonawalla on Sunday assured that the Covishield vaccine, which has received approval for restricted emergency use, is "very safe".
Even before getting the approval from the apex drug controller of India, Serum Institute of India stockpiled about 40-50 million doses of the Covid-19 vaccine, taking a major risk.
As India gears up for the world's largest vaccination programme, the Drugs Controller General of India (DCGI) on Sunday quelled rumours surrounding the COVID-19 vaccines regarding impotency, rubbishing such speculations as "absolute nonsense".
Poonawalla'' remarks came soon after after India's drugs regulator, Drug Controller General of India (DCGI) approved Covishield for restricted emergency use.
Serum Institute of India (SII) Chief Executive Officer Adar Poonawalla on Monday said that the world will see a shortage of the coronavirus vaccine in the first six months of 2021.
"We need to have the government indemnify manufacturers, especially vaccine manufacturers, against all lawsuits. In fact, COVAX and other countries have already started talking about that," Poonawalla said.
Serum Institute of India (SII) CEO Adar Poonawalla on Sunday said the COVID-19 vaccination drive in the country was likely to begin by January, in line with expectations of receiving approvals for emergency-use authorisation of Oxford-AstraZeneca vaccinate candidate by month-end.
Pune-based Serum Institute of India (SII) has collaborated with the University of Oxford and the British-Swedish pharmaceutical company AstraZeneca for making the Covid-19 vaccine, ‘‘Covidshield’‘, and is conducting trials in India.
After holding a review meeting with Prime Minister Narendra Modi on Saturday, Serum Institute of India CEO Adar Poonawalla said that in the process of applying for emergency use authorization of Covishield in the next two weeks. He also said that there is an indication that the Centre may purchase 300-400 million doses by July 2021. "We are in the process of applying for emergency use authorization of Covishield in the next two weeks," Poonawala said.
Top News
Latest News
